The acquisition of our newly licensed Hangzhou facility establishes robust local sourcing capabilities to accelerate and support clinical trials across China

我们新获许可的杭州设施的收购，建立了强大的本地采购能力，以加速并支持在中国各地的临床试验。

HANGZHOU, China

中国杭州

,

，

Nov. 3, 2026

2026年11月3日

/PRNewswire/ -- Zuellig Pharma, a leading healthcare solutions company in Asia, announced the strategic acquisition of a specialized clinical supply facility in Hangzhou, China, strengthening its clinical sourcing capabilities to better support domestic and international clinical trials.

/美通社/ -- 亚洲领先的医疗解决方案公司裕利医药宣布，战略收购位于中国杭州的一家专业临床供应设施，以加强其临床采购能力，更好地支持国内外临床试验。

The Hangzhou facility holds a Drug Distribution License (DDL), enabling Zuellig Pharma to provide local clinical sourcing of comparator drugs and concomitant medications in China. This strengthens Zuellig Pharma's ability to offer compliant, in-market sourcing solutions while streamlining billing processes and creating opportunities for value-added tax (VAT) savings for clinical trial sponsors..

杭州设施持有《药品经营许可证》（DDL），使硕腾医药能够在中国提供对照药和伴随用药的本地临床采购服务。这增强了硕腾医药提供合规、在岸采购解决方案的能力，同时简化了开票流程，并为临床试验申办方创造了节省增值税（VAT）的机会。

Strategically located in the heart of Yangtze River Delta's biopharmaceutical innovation corridor, the Hangzhou facility complements and seamlessly connects to Zuellig Pharma's existing Beijing depot and its global network of over 45 clinical depots. To safeguard product integrity, the new facility is equipped with advanced cold-chain capabilities and precision-controlled environments across temperature-controlled capacities ranging from 15–25°C, 2–8°C, and -20°C..

该杭州设施战略性地坐落于长江三角洲生物医药创新走廊的核心地带，与硕腾医药现有的北京仓库及其遍布全球的45余家临床仓库网络形成互补并实现无缝衔接。为保障产品完整性，新设施配备了先进的冷链能力，并在15–25°C、2–8°C和-20°C等温控范围内提供精准控制的环境。

'Asia is playing an increasingly important role in global clinical research and drug development, and China is a critical market within this ecosystem. This strategic acquisition reflects our continued commitment to investing in the infrastructure and capabilities needed to support the regional and global healthcare needs.

亚洲在全球临床研究和药物开发中正发挥着日益重要的作用，而中国则是这一生态系统中的关键市场。此次战略收购体现了我们持续致力于投资所需的基础设施和能力，以支持区域及全球的医疗健康需求。

By strengthening our clinical trial support network, we are helping our partners accelerate the development of innovative therapies for patients across Asia and beyond,' said John Graham, Group Chief Executive Officer, Zuellig Pharma..

“通过加强我们的临床试验支持网络，我们正在帮助合作伙伴加速为亚洲及更广泛地区的患者开发创新疗法。”——Zuellig Pharma集团首席执行官John Graham表示。

'Our focus remains on removing logistical hurdles to clinical development, ensuring critical supplies reach trial sites and patients safely. The addition of our licensed Hangzhou facility represents a significant step forward in strengthening our clinical trial supply capabilities in China. By bringing local sourcing, and distribution capabilities together, we are enabling our life science partners to conduct both domestic studies and multi-regional clinical trials (MRCTs) with faster cycle times, uncompromised regulatory compliance, and robust cold-chain integrity,' said David Christmas, Executive Vice President of Distribution & Clinical Trial Support..

“我们持续专注于消除临床开发中的物流障碍，确保关键物资安全送达试验机构和患者。我们位于杭州的持牌设施的启用，标志着我们在加强中国临床试验供应能力方面迈出了重要一步。通过整合本地采购和分销能力，我们助力生命科学合作伙伴以更快的周期、毫不妥协的监管合规性以及稳固的冷链完整性，开展国内研究及多区域临床试验（MRCT）。”分销与临床试验支持执行副总裁大卫·克里斯马斯表示。

Zuellig Pharma's Clinical Trial Support business serves as a trusted clinical logistics and sourcing partner to 29 of the world's top 50 pharmaceutical companies and 18 of the top 50 global Contract Research Organizations, delivering integrated end-to-end clinical supply chain solutions worldwide.

硕腾医药的临床试验支持业务是全球50强制药公司中的29家以及全球50强合同研究组织（CRO）中的18家的值得信赖的临床物流和采购合作伙伴，为全球提供一体化的端到端临床试验供应链解决方案。

This strategic expansion underscores Zuellig Pharma's commitment through reliable, sustainable, digitally enabled clinical supply infrastructure, supporting domestic and international research partners in accelerating the development of innovative therapies and improving patient access to healthcare..

此次战略扩张凸显了硕腾医药通过可靠、可持续且数字赋能的临床供应基础设施所作出的承诺，旨在支持国内外研究合作伙伴加速创新疗法的开发，并提升患者对医疗服务的可及性。

About Zuellig Pharma

关于裕利医药

Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multibillion-dollar business covering 18 markets with over 12,000 employees.

硕腾医药是亚洲领先的医疗健康解决方案公司，我们的使命是让我们所服务的社区能够更便捷地获得医疗健康服务。我们提供世界一流的分销、数字化及商业服务，以支持该地区日益增长的医疗健康需求。公司始创于一百年前，已发展成为一家市值数十亿美元的企业，业务覆盖18个市场，拥有超过12,000名员工。

Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world..

我们的员工为超过20万家医疗机构提供服务，并与450多家客户合作，其中包括全球前20大制药公司。

SOURCE Zuellig Pharma

来源：裕利医药